Transplantation papers
Pofolia’s corpus holds 63 papers from Transplantation (2012–2023), each with a short summary. Below, the 20 most-cited, then the most recently added.
At a glance
- Most cited: HLA-Mismatched Renal Transplantation without Maintenance Immunosuppression (2013, 1,019 citations).
- The 20 papers listed have 12,450 citations between them.
- 19 of the 20 with a known journal quartile appeared in a Q1 journal.
- 8 have a free full text (open access).
- Most frequent journals: New England Journal of Medicine, American Journal of Transplantation, Journal of the American Society of Nephrology.
- Published between 2012 and 2021.
Most cited
Ranked by citation count. Because citations accumulate over time, this list naturally leans towards work published a few years ago; for where the field is now, see “recently added”. How to read the signals
HLA-Mismatched Renal Transplantation without Maintenance Immunosuppression
New England Journal of Medicine · 2013 · Q1 · SJR 18.00 · FWCI 53.67 · 1,019 citations · Open access
A long-term follow-up study shows that combined kidney and bone marrow transplantation without ongoing immunosuppression can achieve sustained graft survival in a small cohort of patients.
Evolution and Clinical Pathologic Correlations of De Novo Donor-Specific HLA Antibody Post Kidney Transplant
American Journal of Transplantation · 2012 · Q1 · SJR 3.00 · FWCI 38.75 · 932 citations
In 15% of kidney transplant recipients (47/315) without pre-existing antibodies, de novo donor-specific HLA antibodies (dnDSA) developed a median of 4.6 years post-transplant, significantly reducing 10-year graft survival to 57% compared to 96% in those without dnDSA.
Complement-Binding Anti-HLA Antibodies and Kidney-Allograft Survival
New England Journal of Medicine · 2013 · Q1 · SJR 18.00 · FWCI 46.74 · 837 citations · Open access
Kidney transplant recipients with complement-binding donor-specific anti-HLA antibodies after surgery had a significantly lower 5-year graft survival rate (54%) compared to those without such antibodies (94%).
Consensus Guidelines on the Testing and Clinical Management Issues Associated With HLA and Non-HLA Antibodies in Transplantation
Transplantation · 2012 · Q1 · SJR 1.00 · FWCI 32.56 · 778 citations
New guidelines recommend using sensitive solid-phase immunoassay (SPI) technology, particularly single-antigen bead assays, for detecting human leukocyte antigen (HLA) antibodies in transplant recipients, as these can identify antibodies missed by older methods.
A 2018 Reference Guide to the Banff Classification of Renal Allograft Pathology
Transplantation · 2018 · Q1 · SJR 1.00 · FWCI 37.14 · 765 citations
This review provides a consolidated and illustrated reference guide to the Banff Classification of Kidney Allograft Pathology, incorporating all updates through 2017.
Belatacept and Long-Term Outcomes in Kidney Transplantation
New England Journal of Medicine · 2016 · Q1 · SJR 18.00 · FWCI 69.33 · 762 citations · Open access
After 7 years, kidney transplant recipients on belatacept-based immunosuppression showed a 43% reduction in the risk of death or graft loss compared to those on cyclosporine, with significantly improved kidney function.
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 Genotype and Tacrolimus Dosing
Clinical Pharmacology & Therapeutics · 2015 · Q1 · SJR 1.00 · FWCI 26.02 · 696 citations
New CPIC guidelines recommend adjusting tacrolimus dosing based on CYP3A5 genotype to improve immunosuppression after transplantation.
KDIGO Clinical Practice Guideline on the Evaluation and Management of Candidates for Kidney Transplantation
Transplantation · 2020 · Q1 · SJR 1.00 · FWCI 55.30 · 692 citations
This guideline provides updated, evidence-based recommendations for healthcare professionals worldwide on evaluating and managing potential kidney transplant candidates.
Therapeutic Drug Monitoring of Tacrolimus-Personalized Therapy: Second Consensus Report
Therapeutic Drug Monitoring · 2019 · Q2 · FWCI 44.61 · 661 citations
This second consensus report updates recommendations for personalizing tacrolimus therapy using therapeutic drug monitoring (TDM), incorporating advances in pharmacokinetics, pharmacogenetics, and biomarkers.
Long-Term Survival after Kidney Transplantation
New England Journal of Medicine · 2021 · Q1 · SJR 18.00 · FWCI 63.29 · 614 citations
This review synthesizes decades of data on kidney transplant outcomes, highlighting factors that impede long-term survival and addressing disparities in care.
Cell-Free DNA and Active Rejection in Kidney Allografts
Journal of the American Society of Nephrology · 2017 · Q1 · SJR 3.00 · FWCI 27.50 · 576 citations · Open access
Donor-derived cell-free DNA (dd-cfDNA) in blood can noninvasively differentiate kidney transplant rejection from other injuries, with levels above 1.0% indicating a probability of active rejection.
Induction Therapy With Autologous Mesenchymal Stem Cells in Living-Related Kidney Transplants
JAMA · 2012 · Q1 · SJR 5.00 · FWCI 45.46 · 557 citations
Autologous mesenchymal stem cells (MSCs) used as induction therapy in kidney transplants significantly reduced acute rejection rates and opportunistic infections compared to standard antibody induction, while also improving early renal function.
Antibody-Mediated Rejection of Solid-Organ Allografts
New England Journal of Medicine · 2018 · Q1 · SJR 18.00 · FWCI 28.94 · 533 citations
This review highlights current management strategies for antibody-mediated rejection in solid-organ transplant recipients.
OPTN/SRTR 2016 Annual Data Report: Kidney
American Journal of Transplantation · 2018 · Q1 · SJR 3.00 · FWCI 73.95 · 502 citations · Open access
Kidney transplant data from 2016 show improved short- and long-term graft survival and a decrease in waitlisted candidates for the first time in over a decade, alongside an increase in deceased donor transplants.
An economic assessment of contemporary kidney transplant practice
American Journal of Transplantation · 2018 · Q1 · SJR 3.00 · FWCI 27.09 · 447 citations · Open access
All kidney transplant types, including those using marginal donors or incompatible living donors, offer improved survival and are cost-effective compared to dialysis over a 10-year period.
OPTN/SRTR 2015 Annual Data Report: Kidney
American Journal of Transplantation · 2017 · Q1 · SJR 3.00 · FWCI 61.74 · 443 citations · Open access
The 2015 kidney allocation system led to increased transplants for Black candidates and those with high antibody levels (98%-100% PRA), but decreased transplants for older adults (65+).
Macrophage-to-Myofibroblast Transition Contributes to Interstitial Fibrosis in Chronic Renal Allograft Injury
Journal of the American Society of Nephrology · 2017 · Q1 · SJR 3.00 · FWCI 12.66 · 429 citations · Open access
A novel mechanism where macrophages transform into myofibroblasts drives interstitial fibrosis, a key cause of kidney transplant failure. These transitional cells constitute about half of the fibrotic cells and their numbers correlate with reduced graft function.
Single-Cell Transcriptomics of a Human Kidney Allograft Biopsy Specimen Defines a Diverse Inflammatory Response
Journal of the American Society of Nephrology · 2018 · Q1 · SJR 3.00 · FWCI 28.17 · 420 citations
This study applies single-cell RNA sequencing to a human kidney transplant biopsy, revealing 16 distinct cell types and identifying novel segment-specific inflammatory responses in rejection.
New National Allocation Policy for Deceased Donor Kidneys in the United States and Possible Effect on Patient Outcomes
Journal of the American Society of Nephrology · 2014 · Q1 · SJR 3.00 · FWCI 31.89 · 415 citations
A new US kidney allocation policy, using a Kidney Donor Profile Index (KDPI) and prioritizing certain candidates, is projected to increase median allograft survival by 0.25 years compared to the previous system.
Incidence and Impact of De Novo Donor-Specific Alloantibody in Primary Renal Allografts
Transplantation · 2013 · Q1 · SJR 1.00 · FWCI 28.12 · 372 citations
In primary kidney transplant patients, 25% developed de novo donor-specific antibodies (dnDSA) within 10 years, with 20% incidence by 5 years and 24% graft loss within 3 years of dnDSA appearance.
Recently added
The Banff 2022 Kidney Meeting Report: Reappraisal of microvascular inflammation and the role of biopsy-based transcript diagnostics
American Journal of Transplantation · 2023 · Q1 · SJR 3.00 · FWCI 52.46 · 263 citations · Open access
The Banff 2022 meeting established new criteria for 'Probable AMR' (donor-specific antibodies with some AMR features) and 'Microvascular Inflammation, DSA-negative and C4d-negative' (unexplained microvascular inflammation), impacting kidney transplant rejection diagnosis.
Long-Term Survival after Kidney Transplantation
New England Journal of Medicine · 2021 · Q1 · SJR 18.00 · FWCI 63.29 · 614 citations
This review synthesizes decades of data on kidney transplant outcomes, highlighting factors that impede long-term survival and addressing disparities in care.
OPTN/SRTR 2019 Annual Data Report: Kidney
American Journal of Transplantation · 2021 · Q1 · SJR 3.00 · FWCI 55.66 · 370 citations · Open access
Kidney transplants in the US hit a record 24,273 in 2019, up annually since 2015, yet only 25% of waitlisted patients receive a deceased-donor kidney within 5 years, with significant regional variation (15.5%-67.8%).
KDIGO Clinical Practice Guideline on the Evaluation and Management of Candidates for Kidney Transplantation
Transplantation · 2020 · Q1 · SJR 1.00 · FWCI 55.30 · 692 citations
This guideline provides updated, evidence-based recommendations for healthcare professionals worldwide on evaluating and managing potential kidney transplant candidates.
Recommended Treatment for Antibody-mediated Rejection After Kidney Transplantation: The 2019 Expert Consensus From the Transplantion Society Working Group
Transplantation · 2019 · Q1 · SJR 1.00 · FWCI 18.98 · 334 citations
A 2019 expert consensus from The Transplantation Society recommends treatment for antibody-mediated rejection (AMR) in kidney transplant recipients, largely based on expert opinion due to a lack of high-level evidence.
Prediction system for risk of allograft loss in patients receiving kidney transplants: international derivation and validation study
BMJ · 2019 · Q1 · SJR 1.00 · FWCI 27.55 · 347 citations · Open access
A new risk score, called iBox, accurately predicts long-term kidney transplant failure, outperforming previous scores and showing generalizability across diverse patient groups and clinical settings.
Therapeutic Drug Monitoring of Tacrolimus-Personalized Therapy: Second Consensus Report
Therapeutic Drug Monitoring · 2019 · Q2 · FWCI 44.61 · 661 citations
This second consensus report updates recommendations for personalizing tacrolimus therapy using therapeutic drug monitoring (TDM), incorporating advances in pharmacokinetics, pharmacogenetics, and biomarkers.
OPTN/SRTR 2017 Annual Data Report: Kidney
American Journal of Transplantation · 2019 · Q1 · SJR 3.00 · FWCI 45.22 · 327 citations · Open access
Kidney transplantation in 2017 saw rising deceased donor rates and declining waitlists, with improved allograft survival, yet access remains uneven and living donor transplant rates fell, widening racial disparities.
Journals in this field
The journals that publish most of this field’s papers. Quartile (Q1–Q4), SJR and h-index are from SCImago Journal Rank; “in this field” is how many of the journal’s pooled papers belong here. What is a Q1 journal? · What is the h-index?
| Journal | Quartile | SJR | h-index | In this field | Summaries |
|---|---|---|---|---|---|
| American Journal of Transplantation | Q1 | 3.00 | 238 | 14 | 14 |
| Journal of the American Society of Nephrology | Q1 | 3.00 | 342 | 12 | 14 |
| Transplantation | Q1 | 1.00 | 230 | 11 | 12 |
| New England Journal of Medicine | Q1 | 18.00 | 1275 | 10 | 376 |
| JAMA | Q1 | 5.00 | 818 | 3 | 114 |
| BMJ | Q1 | 1.00 | 543 | 2 | 47 |
| Endocrine Reviews | Q1 | 9.00 | 326 | 1 | 11 |
| Hepatology | Q1 | 7.00 | 424 | 1 | 17 |
Every journal in Transplantation (Q1–Q4) →
Add this field to your daily feed
Pick your interests and new work in your area arrives every day, summarised. Full summaries live in the app.
Open the app